StockNews.AI

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

StockNews.AI • 12 hours

GHDXNTRAILMN
High Materiality8/10

Information

Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 3...

Original source

AI Summary

MYGN expects Q4 2025 revenues of $207-$209 million. 2025 total revenues are forecasted at $822-$824 million. 2026 financial guidance projects revenues of $860-$880 million, indicating 6% growth. Adjusted EBITDA for 2026 is expected between $37-$49 million, up 43%. Preliminary results are subject to audit and may change.

Sentiment Rationale

The revenue projections for 2026 indicate positive growth compared to 2025. Historically, guidance above past performance can drive stock prices higher.

Trading Thesis

Immediate investor reactions are expected around the upcoming earnings call and healthcare conference. Positive early guidance may boost interest and share prices in the near term.

Market-Moving

  • MYGN expects Q4 2025 revenues of $207-$209 million.
  • 2025 total revenues are forecasted at $822-$824 million.
  • 2026 financial guidance projects revenues of $860-$880 million, indicating 6% growth.

Key Facts

  • MYGN expects Q4 2025 revenues of $207-$209 million.
  • 2025 total revenues are forecasted at $822-$824 million.
  • 2026 financial guidance projects revenues of $860-$880 million, indicating 6% growth.
  • Adjusted EBITDA for 2026 is expected between $37-$49 million, up 43%.
  • Preliminary results are subject to audit and may change.

Companies Mentioned

  • GHDX (GHDX)
  • NTRA (NTRA)
  • ILMN (ILMN)

Earnings

The financial guidance is critical for investors evaluating MYGN's performance expectations. Upcoming earnings and the healthcare conference will likely attract investor attention.

Myriad Genetics Reports Preliminary Financial Results for 2025 and Offers 2026 Guidance

SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, has announced select unaudited preliminary financial results for the fourth quarter and the full year ended December 31, 2025. The company also provided financial guidance for the upcoming year of 2026.

Preliminary Financial Results for Q4 and Full Year 2025

For the fourth quarter of 2025, Myriad Genetics anticipates total revenues between $207 million and $209 million. Additionally, the projected total revenues for the entire year of 2025 are expected to fall between $822 million and $824 million. The actual financial results will be formally disclosed during an earnings call scheduled for February 2026.

These preliminary results are subject to Myriad Genetics' typical year-end accounting procedures and will undergo an external audit by the company’s independent registered public accounting firm. Consequently, these preliminary figures may be adjusted based on the finalization of the company’s year-end financial statements.

Financial Guidance for 2026

Myriad Genetics has provided preliminary financial guidance for 2026, which indicates:

  • Revenue: Expected to range from $860 million to $880 million, reflecting a growth of approximately 6% compared to the previous year’s midpoint revenue estimate.
  • Adjusted Gross Margin: Projected between 68% and 69%, accounting for impacts from new product launches.
  • Adjusted EBITDA: Forecasted between $37 million and $49 million, indicating an anticipated growth of around 43% compared to the 2025 guidance.

This guidance assumes currency rates as of January 12, 2026.

It is important to note that Myriad Genetics does not provide forward-looking guidance on a GAAP basis for the measures on which it offers non-GAAP guidance, citing the complexity and unpredictable nature of certain financial adjustments that may be necessary.

Understanding Myriad Genetics and Its Market Position

Myriad Genetics specializes in molecular diagnostic testing and precision medicine, playing a pivotal role in advancing health and well-being through innovative medical solutions. The company develops comprehensive molecular tests that assist in assessing the risk of disease and guiding treatment decisions, thereby enhancing patient care and reducing healthcare expenditures.

For more details on Myriad Genetics and its offerings, please visit www.myriad.com.

Forward-Looking Statements and Cautionary Notes

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including anticipated fourth quarter and full year 2025 revenues, as well as 2026 financial guidance. These statements are based on current management expectations and are subject to various risks and uncertainties.

Key risks impacting Myriad Genetics include potential declines in sales and profit margins of existing tests, challenges related to achieving revenue growth targets, and changes in insurance reimbursement levels. Investors are encouraged to review these factors carefully.

Related News